Cardiotoxicity

Questions discussed in this category

How do you incorporate PD-L1 blockade?

What is the utility and recommendation for adding troponin and/or BNP to echocardiograms to screen for cardiac dysfunction In breast cancer patients receiving anthracycline based regimens?

1 Answer available

How do you approach the re-challenge with trastuzumab in metastatic HER2+ patients who develop cardiomyopathy on trastuzumab/pertuzumab with subsequent improvement with discontinuation?

Do you repeat the loading dose of trastuzumab?

1 Answer available

How do you manage elderly women with high-risk HER2 positive disease with baseline low ejection fraction?

For example, in a patient > 70 years old?

1 Answer available

What neoadjuvant chemotherapy regimen would you choose for a young patient with HER2 positive breast cancer with reduced ejection fraction?

Is there any evidence to use trastuzumab and pertuzumab without doxorubicin?

1 Answer available

How do you assess the risk of cardiotoxicity from HER2+ agents?

1 Answer available

What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

1 Answer available

How do you minimize the risk of cardiotoxicity in metastatic Her2 + breast cancer patients who are receiving trastuzumab and have a history of pre-existing cardiac disease?

1 Answer available

Papers discussed in this category

Cochrane Database Syst Rev, 2008 Apr 16

Cardioprotective interventions for cancer patients receiving anthracyclines.

Eur. J. Cancer, 2013 May 22

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

The Lancet. Oncology, 2013-10

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Engl. J. Med., 2017-07-13

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

The Cochrane database of systematic reviews, 2011 Jun 15

Cardioprotective interventions for cancer patients receiving anthracyclines.

JACC. CardioOncology, 2019 Sep 24

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

JACC. CardioOncology, 2024 Apr 16

Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: : CardioOncology Controversies in Cardio-Oncology.

JACC. CardioOncology, 2023 May 02

The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer.

Heart failure reviews, 2025 Feb 17

The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.

The Lancet. Oncology, 2017-08

Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03-10

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

The Lancet. Oncology, 2019-06

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

Cardiotoxicity

Questions discussed in this category

Papers discussed in this category

Related Topics